We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Jupiter Japan Income - seeking companies able to grow cash flow

Investments can go down as well as up so there is always a danger that you could get back less than you invest. Nothing here is personalised advice, if unsure you should seek advice.
  • Fund underperformed peers over the past year as its investments in large, high-yielding companies dragged on performance
  • Dan Carter believes Japan’s ageing population will pose challenges for domestic consumption so the fund features little exposure to the consumer sectors
  • We would like to see the manager establish a more consistent track record of adding value through stock selection

Our view

Dan Carter has managed the Jupiter Japan Income Fund since June 2016 and hired assistant manager Mitesh Patel in October 2016. Together they form a well-balanced team, which combines Mitesh Patel’s quantitative background and Dan Carter’s more judgement-based approach.

Our analysis of Dan Carter’s track record reveals he has delivered a lower return than the average fund in the sector and since October 2013. This incorporates his track record as lead manager of Jupiter JGF Japan Select, and the short time he has been at the helm of Jupiter Japan Income, although past performance is not a guide to the future.

We would like to see him establish a longer track record, spanning all market conditions, and accrue a more consistent history of adding value through astute stock selection before considering the fund for the Wealth 150+ list of our favourite funds across the major sectors.

Portfolio review

Dan Carter adopts a similar approach to that of his well-regarded predecessor Simon Somerville – he seeks companies with management teams that have a strong track record of reinvesting cash wisely to grow the business, or paying it out to shareholders as dividends. He is happy to invest in companies that offer lower yields, as long as there is scope to grow dividends.

Although this approach paid off for his predecessor over the long term, the fund has marginally underperformed its benchmark under Dan Carter’s short tenure so far, though past performance is no guide to the future.

Annual Percentage Growth
Aug 12 -
Aug 13
Aug 13 -
Aug 14
Aug 14 -
Aug 15
Aug 15 -
Aug 16
Aug 16 -
Aug 17
Jupiter Japan Income 20.9 -0.2 20.7 17.6 17.8
FTSE Japan 27.7 3.0 13.9 21.1 17.0

Past performance is not a guide to the future. Source: Lipper IM* to 31/08/2017

Performance was held back over the past year by the fund’s large, high-yielding companies, which underperformed the rapidly rising stock market. Broadband provider and mobile communication company KDDI Corporation, for example, performed poorly which proved particularly painful given the company is one of the fund’s largest investments. Companies involved in the basic materials and oil & gas sectors performed well but the fund had little exposure to these areas.


Dan Carter believes the willingness and ability of Japanese companies to increase dividends is growing, partly due to the country’s new Corporate Governance Code which aims to put shareholder’s interests at the forefront of corporate decision-making. This has already caused an increase in the proportion of earnings being paid to shareholders as dividends, and companies buying back shares at a premium to their market value, according to the manager.

Nevertheless, Japan faces challenges. Falling birth rates, increasing life expectancy and low immigration mean the country’s population is one of the oldest in the world. The manager expects consumer spending to fall as the population ages and therefore the fund has limited exposure to the consumer goods and services sectors.

He believes healthcare will become increasingly important in Japan as the population grows older, but this is widely recognised by other investors and many healthcare companies are currently overvalued, in his view. The fund’s healthcare exposure therefore focuses on a small number of investments that the manager believes to be attractively valued. This includes recent purchase Eiken Chemical, a market leader in providing blood tests. Their tests allow a user to screen for signs of colorectal cancer, which is prevalent amongst the older generations.

Please read the key features/key investor information document in addition to the information above.

Important information - Please remember the value of investments, and any income from them, can fall as well as rise so you could get back less than you invest. This article is provided to help you make your own investment decisions, it is not advice. If you are unsure of the suitability of an investment for your circumstances please seek advice. No news or research item is a personal recommendation to deal.

Want our latest research sent direct to your inbox?

Our expert research team provide regular updates on a wide range of funds.

Sign up today